The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study
Abstract Background The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid fun...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Pediatrics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12887-025-05452-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571317327495168 |
|---|---|
| author | Orian Raviv Yael Lebenthal Michal Yackobovitch-Gavan Eyal Cohen-Sela Shlomo Almashanu Ronella Marom Jacky Herzlich Liran Hiersch Avivit Brener |
| author_facet | Orian Raviv Yael Lebenthal Michal Yackobovitch-Gavan Eyal Cohen-Sela Shlomo Almashanu Ronella Marom Jacky Herzlich Liran Hiersch Avivit Brener |
| author_sort | Orian Raviv |
| collection | DOAJ |
| description | Abstract Background The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid function as measured by the National Newborn Screening (NBS) Program and identified contributory factors. Methods An observational large-scale study of mother-infant dyads of liveborn infants delivered between 2011 and 2022. The Israeli NBS Program thyroid dataset [total thyroxine (TT4) obtained between 36‐72 h after delivery] was linked with the electronic medical records of mothers and their infants born at Lis Maternity and Women's Hospital, to generate a unified database. The MDClone big data platform was utilized to extract maternal, perinatal, and neonatal characteristics from the medical records of mother-infant dyads. Only term liveborn infants born to mothers without documented thyroid disease and/or chronic medication administration, except for SSRIs, were included in order to minimize potential confounding effects on the infant's thyroid function. Group stratification relied on the documentation of gestational SSRIs treatment. The variables of interest were maternal, pregnancy, delivery, and perinatal characteristics of the mother–infant dyads. Multivariable forward linear regression model was applied to evaluate explanatory variables for newborn total thyroxine (TT4) levels. Results Out of 105,928 infant-mother dyads, 2321(2.2%) mothers had been treated with SSRIs during pregnancy. The SSRI-treated mothers were older (34.8 ± 4.7 vs 32.6 ± 4.8 years, p < 0.001) and had a higher pre-pregnancy body mass index (23.4 ± 4.5 vs 22.7 ± 4.1, p < 0.001), but similar mean weight gain (13 kg) during pregnancy. Cesarean delivery was more common among SSRI-treated mothers than in the general population (p < 0.001). Infants of SSRI-treated mothers had lower WHO-classified birthweight z-scores (-0.25 ± 0.93 vs -0.04 ± 0.92, p < 0.001) and a higher rate of small-for-gestational-age infants (13.4% vs 8.2%, p < 0.001). A multivariable forward linear regression model revealed that SSRI treatment during pregnancy was not a significant contributor to TT4 levels (p = 0.497). Conclusions SSRI treatment during pregnancy had no direct effect upon the newborn's adaptation of the hypothalamic-pituitary-thyroidal axis, but several other maternal and delivery characteristics were revealed to possibly impact newborn thyroid function. |
| format | Article |
| id | doaj-art-990d7c5a492b4b4b92907ac5f0b3c71a |
| institution | Kabale University |
| issn | 1471-2431 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pediatrics |
| spelling | doaj-art-990d7c5a492b4b4b92907ac5f0b3c71a2025-02-02T12:42:54ZengBMCBMC Pediatrics1471-24312025-01-0125111110.1186/s12887-025-05452-8The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort studyOrian Raviv0Yael Lebenthal1Michal Yackobovitch-Gavan2Eyal Cohen-Sela3Shlomo Almashanu4Ronella Marom5Jacky Herzlich6Liran Hiersch7Avivit Brener8Institute of Pediatric Endocrinology, Dana Dwek Children’s Hospital, Tel Aviv Sourasky Medical CenterInstitute of Pediatric Endocrinology, Dana Dwek Children’s Hospital, Tel Aviv Sourasky Medical CenterDepartment of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv UniversityInstitute of Pediatric Endocrinology, Dana Dwek Children’s Hospital, Tel Aviv Sourasky Medical CenterThe National Newborn Screening Program, Ministry of HealthFaculty of Medicine, Tel Aviv UniversityFaculty of Medicine, Tel Aviv UniversityFaculty of Medicine, Tel Aviv UniversityInstitute of Pediatric Endocrinology, Dana Dwek Children’s Hospital, Tel Aviv Sourasky Medical CenterAbstract Background The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid function as measured by the National Newborn Screening (NBS) Program and identified contributory factors. Methods An observational large-scale study of mother-infant dyads of liveborn infants delivered between 2011 and 2022. The Israeli NBS Program thyroid dataset [total thyroxine (TT4) obtained between 36‐72 h after delivery] was linked with the electronic medical records of mothers and their infants born at Lis Maternity and Women's Hospital, to generate a unified database. The MDClone big data platform was utilized to extract maternal, perinatal, and neonatal characteristics from the medical records of mother-infant dyads. Only term liveborn infants born to mothers without documented thyroid disease and/or chronic medication administration, except for SSRIs, were included in order to minimize potential confounding effects on the infant's thyroid function. Group stratification relied on the documentation of gestational SSRIs treatment. The variables of interest were maternal, pregnancy, delivery, and perinatal characteristics of the mother–infant dyads. Multivariable forward linear regression model was applied to evaluate explanatory variables for newborn total thyroxine (TT4) levels. Results Out of 105,928 infant-mother dyads, 2321(2.2%) mothers had been treated with SSRIs during pregnancy. The SSRI-treated mothers were older (34.8 ± 4.7 vs 32.6 ± 4.8 years, p < 0.001) and had a higher pre-pregnancy body mass index (23.4 ± 4.5 vs 22.7 ± 4.1, p < 0.001), but similar mean weight gain (13 kg) during pregnancy. Cesarean delivery was more common among SSRI-treated mothers than in the general population (p < 0.001). Infants of SSRI-treated mothers had lower WHO-classified birthweight z-scores (-0.25 ± 0.93 vs -0.04 ± 0.92, p < 0.001) and a higher rate of small-for-gestational-age infants (13.4% vs 8.2%, p < 0.001). A multivariable forward linear regression model revealed that SSRI treatment during pregnancy was not a significant contributor to TT4 levels (p = 0.497). Conclusions SSRI treatment during pregnancy had no direct effect upon the newborn's adaptation of the hypothalamic-pituitary-thyroidal axis, but several other maternal and delivery characteristics were revealed to possibly impact newborn thyroid function.https://doi.org/10.1186/s12887-025-05452-8Antidepressant drugIn vitro fertilization (IVF)OxytocinPregnancyThyroid function |
| spellingShingle | Orian Raviv Yael Lebenthal Michal Yackobovitch-Gavan Eyal Cohen-Sela Shlomo Almashanu Ronella Marom Jacky Herzlich Liran Hiersch Avivit Brener The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study BMC Pediatrics Antidepressant drug In vitro fertilization (IVF) Oxytocin Pregnancy Thyroid function |
| title | The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study |
| title_full | The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study |
| title_fullStr | The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study |
| title_full_unstemmed | The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study |
| title_short | The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study |
| title_sort | association between gestational selective serotonin reuptake inhibitor ssri treatment and newborn thyroid screen a large scale cohort study |
| topic | Antidepressant drug In vitro fertilization (IVF) Oxytocin Pregnancy Thyroid function |
| url | https://doi.org/10.1186/s12887-025-05452-8 |
| work_keys_str_mv | AT orianraviv theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT yaellebenthal theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT michalyackobovitchgavan theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT eyalcohensela theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT shlomoalmashanu theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT ronellamarom theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT jackyherzlich theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT liranhiersch theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT avivitbrener theassociationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT orianraviv associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT yaellebenthal associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT michalyackobovitchgavan associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT eyalcohensela associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT shlomoalmashanu associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT ronellamarom associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT jackyherzlich associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT liranhiersch associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy AT avivitbrener associationbetweengestationalselectiveserotoninreuptakeinhibitorssritreatmentandnewbornthyroidscreenalargescalecohortstudy |